Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.70224 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Jeffrey Cummings und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of Las Vegas, UNLV, Las Vegas, NV, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized, Cognition. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIA NIH HHS, Biogen.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION In EMERGE (NCT02484547), participants receiving aducanumab had significantly less progression versus placebo on all prespecified clinical endpoints at week 78. Here, we explicate the clinical meaningfulness of these treatment effects by analyzing item‐level data and the persistence of treatment benefit. METHODS Participants with early Alzheimer's disease (AD) were stratified by apolipoprotein E ( APOE ) ε4 status and randomized (1:1:1) to receive low‐ or high‐dose aducanumab, or placebo. Prespecified principal component analyses (PCAs) per the Statistical Analysis Plan were followed by post hoc examination of individual domains/items across all five clinical endpoints. Progression analysis assessed reduction in clinical decline. RESULTS High‐dose aducanumab demonstrated clinically meaningful slowing of progression across clinical endpoints measuring cognition, daily function, and behavioral symptoms. Delay of progression over 18 months was consistent across measures; treatment effects increased over time. DISCUSSION Across multiple analyses aducanumab slowed cognitive decline, prolonged functional independence, and attenuated behavioral symptoms in participants with early AD. These outcomes comprise the elements of a clinically meaningful response to treatment. Highlights Endpoints in EMERGE assessed different aspects of cognition, daily function, and behavioral symptoms. Treatment benefits were observed across subdomains on all five clinical endpoints. Aducanumab meaningfully slowed disease progression in participants with early AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Las Vegas, UNLV, Las Vegas, NV, USA.
- Toronto Memory Program, Toronto, ON, Canada.
- Biogen, Cambridge, Massachusetts, USA.
- Alzheimercentrum, AUmC, Amsterdam, the Netherlands.
- Scottish Brain Sciences, Edinburgh, UK.
- Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Förderung
- NIGMS NIH HHS
- NIA NIH HHS
- Biogen
Zitieren
APA
Cummings, J., Cohen, S., Murphy, J., Brothers, H. M., Nejati, M., Forrestal, F., de Moor, C., O'Gorman, J., Harrison, J., Jaeger, J., Mummery, C. J., Porsteinsson, A. P., Potashman, M., Tian, Y., Yang, L., He, P., & Haeberlein, S. B. (2025). Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70224
Vancouver
Cummings J, Cohen S, Murphy J, Brothers HM, Nejati M, Forrestal F, et al. Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70224
BibTeX
@article{Cummings2025,
author = {Cummings, Jeffrey and Cohen, Sharon and Murphy, Jennifer and Brothers, Holly M and Nejati, Mina and Forrestal, Fiona and de Moor, Carl and O'Gorman, John and Harrison, John and Jaeger, Judith and Mummery, Catherine Jane and Porsteinsson, Anton P and Potashman, Michele and Tian, Ying and Yang, Lili and He, Ping and Haeberlein, Samantha Budd},
title = {Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.70224}
}
EUVIMED